Top 20 Oncology Companies of 2025

Shots: ADCs, cell therapies, and radioligand therapies are reshaping oncology, while biopharma companies focus on smarter trials, patient-first approaches, and faster access to bridge unmet needs in cancer care In 2024, the global oncology market was valued at $225.01B and is projected to reach $668.26B by 2034, reflecting a strong CAGR of 11.5% from 2025…

ByPrince GiriSeptember 3, 2025

TOP 20

Top 20 Biopharma Companies of 2025

Shots: Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…

ByPrince GiriApril 24, 2025

NEWS

Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Shots: The P-III (TALAPRO-2) trial assessed Talzenna + Xtandi vs PBO + Xtandi in mCRPC ± HRRm pts for >4yr. (mFU: 52.5mos.) that were randomized into 2 Arms (A1: no genetic selection & A2: HRRm pts) A1 showed reduced death risk by 20% & mOS of 45.8 vs 37mos. while A2 depicted death risk…

ByRidhi RastogiFebruary 14, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2024

Shots: The Fourth quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Roche's acquisition of Poseida Therapeutics for ~$1.5B This quarter also showcased multiple clinical trial results including Pfizer's P-III Study Data of Talzenna + Xtandi to treat mCRPC …

ByDipanshu DixitJanuary 13, 2025

INSIGHTS+

Top Performing Drug – Xtandi (December Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readers Xtandi is indicated for the treatment of certain prostate cancers PharmaShots presents a concise take on the key features of Xtandi with…

BySenior EditorDecember 28, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2020

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…

ByDipanshu DixitJanuary 14, 2021

Top 20 Oncology Companies of 2025

Top 20 Biopharma Companies of 2025

Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)

PharmaShots’ Key Highlights of Fourth Quarter 2024

Top Performing Drug – Xtandi (December Edition)

PharmaShots’ Key Highlights of Fourth Quarter 2020

Contact US

OUR INFORMATION

FOLLOW US